

Printing date 11/14/2022

Revision date 11/14/2022

Page 1/7


1 Identification

- · Product identifier
- Trade name: CD4 Chimeric Monoclonal Antibody (Clone YNB46.1.8)
- · Article number: 37161
- **Application of the substance / the mixture** This product is for research use - Not for human or veterinary diagnostic or therapeutic use.
- · Details of the supplier of the safety data sheet

• **Manufacturer/Supplier:** Cayman Chemical Co. 1180 E. Ellsworth Rd. Ann Arbor, MI 48108 USA

 Information department: Product safety department
 Emergency telephone number: During normal opening times: +1 (734) 971-3335 US/CANADA: 800-424-9300 Outside US/CANADA: 703-741-5970

2 Hazard(s) identification



The product is not classified, according to the Globally Harmonized System (GHS).

- · Label elements
- · GHS label elements None
- · Hazard pictograms None
- · Signal word None
- · Hazard statements None
- Classification system:

• NFPA ratings (scale 0 - 4)



· HMIS-ratings (scale 0 - 4)

HEALTHImage: OFIREImage: OREACTIVITYReactivity = 0

(Contd. on page 2)

US

Printing date 11/14/2022

Revision date 11/14/2022

(Contd. from page 1)

Trade name: CD4 Chimeric Monoclonal Antibody (Clone YNB46.1.8)

· Other hazards

- Results of PBT and vPvB assessment
- **PBT:** Not applicable.
- · vPvB: Not applicable.

3 Composition/information on ingredients

· Chemical characterization: Mixtures

- · Description: Mixture of the substances listed below with nonhazardous additions.
- · Dangerous components: None

· Other ingredients			
CAS: 7732-18-5	Water	98.89%	
RTECS: ZC0110000			
	PBS	0.99%	
	Protein	0.1%	
	ProClin™ 300	0.02%	

4 First-aid measures

- Description of first aid measures
- · General information: No special measures required.
- After inhalation: Supply fresh air; consult doctor in case of complaints.
- After skin contact: Generally the product does not irritate the skin.
- · After eye contact: Rinse opened eye for several minutes under running water.
- · After swallowing: If symptoms persist consult doctor.
- Information for doctor:
- **Most important symptoms and effects, both acute and delayed** May cause anemia, cough, CNS depression, drowsiness, headache, heart damage, lassitude (weakness, exhaustion), liver damage, narcosis, reproductive effects, teratogenic effects.
- No further relevant information available. • Indication of any immediate medical attention and special treatment needed No further relevant information available.

5 Fire-fighting measures

- · Extinguishing media
- Suitable extinguishing agents: Use fire fighting measures that suit the environment. A solid water stream may be inefficient.
- Special hazards arising from the substance or mixture No further relevant information available.
- Advice for firefighters
- · Protective equipment: No special measures required.

6 Accidental release measures

· Personal precautions, protective equipment and emergency procedures Not required.

• Environmental precautions: Dilute with plenty of water.

(Contd. on page 3)

US

Printing date 11/14/2022

Revision date 11/14/2022

Trade name: CD4 Chimeric Monoclonal Antibody (Clone YNB46.1.8)

(Contd. from page 2)

- Methods and material for containment and cleaning up: Absorb with liquid-binding material (sand, diatomite, acid binders, universal binders, sawdust).
 Reference to other sections
 - See Section 7 for information on safe handling.
 - See Section 8 for information on personal protection equipment.
- See Section 13 for disposal information.
- Protective Action Criteria for Chemicals

· PAC-1:

None of the ingredients is listed.

· PAC-2:

None of the ingredients is listed.

· PAC-3:

None of the ingredients is listed.

7 Handling and storage

- · Handling:
- Precautions for safe handling No special measures required.
- · Information about protection against explosions and fires: No special measures required.
- · Conditions for safe storage, including any incompatibilities
- Storage: Store in accordance with information listed on the product insert.
- Requirements to be met by storerooms and receptacles: No special requirements.
- Information about storage in one common storage facility: Not required.
- · Further information about storage conditions: None.
- Specific end use(s) No further relevant information available.

8 Exposure controls/personal protection

- Additional information about design of technical systems: No further data; see item 7.
- · Control parameters
- Components with limit values that require monitoring at the workplace:

The product does not contain any relevant quantities of materials with critical values that have to be monitored at the workplace.

- · Additional information: The lists that were valid during the creation were used as basis.
- Exposure controls
- Personal protective equipment:
- General protective and hygienic measures: The usual precautionary measures for handling chemicals should be followed. • Breathing equipment: Not required.
- Breathing equipment: Not require
- Protection of hands:

The glove material has to be impermeable and resistant to the product/ the substance/ the preparation. Due to missing tests no recommendation to the glove material can be given for the product/ the preparation/ the chemical mixture.

Selection of the glove material on consideration of the penetration times, rates of diffusion and the degradation

• Material of gloves

The selection of the suitable gloves does not only depend on the material, but also on further marks of quality and varies from manufacturer to manufacturer. As the product is a preparation of several substances, the resistance of the glove material can not be calculated in advance and has therefore to be checked prior to the application.

Printing date 11/14/2022

Revision date 11/14/2022

Trade name: CD4 Chimeric Monoclonal Antibody (Clone YNB46.1.8)

• Penetration time of glove material The exact break through time has to be found out by the manufacturer of the protective gloves and has to be observed.

• Eye protection: Goggles recommended during refilling.

9 Physical and chemical properties

General Information	
Appearance: Form: Color: Odor: Storage Buffer Odor threshold: Formulation	Liquid According to product specification Odorless PBS with 0.02% ProClin™ 300 Not determined. 200 µg of protein A-affinity purified monoclonal antibody
pH-value:	Not determined.
Change in condition Melting point/Melting range: Boiling point/Boiling range:	0 °C (32 °F) 100 °C (212 °F)
Flash point:	Not applicable.
Flammability (solid, gaseous):	Not applicable.
Decomposition temperature:	Not determined.
Auto igniting:	Product is not selfigniting.
Danger of explosion:	Product does not present an explosion hazard.
Explosion limits: Lower: Upper:	Not determined. Not determined.
Vapor pressure at 20 °C (68 °F):	23 hPa (17.3 mm Hg)
Density at 20 °C (68 °F): Relative density Vapor density Evaporation rate	1 g/cm³ (8.345 lbs/gal) Not determined. Not determined. Not determined.
Solubility in / Miscibility with Water:	Fully miscible.
Partition coefficient (n-octanol/wate	er): Not determined.
Viscosity: Dynamic at 20 °C (68 °F): Kinematic:	0.952 mPas Not determined.
Solvent content: Water: VOC content:	98.9 % 0.00 % 0.0 g/l / 0.00 lb/gal
Solids content:	0.1 %

(Contd. from page 3)

Printing date 11/14/2022

Revision date 11/14/2022

Trade name: CD4 Chimeric Monoclonal Antibody (Clone YNB46.1.8)

(Contd. from page 4)

• Other information

No further relevant information available.

10 Stability and reactivity

- · Reactivity No further relevant information available.
- · Chemical stability
- Thermal decomposition / conditions to be avoided:

No decomposition if used according to specifications.

- · Possibility of hazardous reactions No dangerous reactions known.
- Conditions to avoid No further relevant information available.
- · Incompatible materials: No further relevant information available.
- · Hazardous decomposition products: No dangerous decomposition products known.

11 Toxicological information

· Information on toxicological effects

- Acute toxicity:
- Primary irritant effect:
- · on the skin: No irritant effect.
- on the eye: No irritating effect.
- · Sensitization: No sensitizing effects known.
- · Additional toxicological information:

The product is not subject to classification according to internally approved calculation methods for preparations:

When used and handled according to specifications, the product does not have any harmful effects according to our experience and the information provided to us.

· Carcinogenic categories

· IARC (International Agency for Research on Cancer)

None of the ingredients is listed.

• NTP (National Toxicology Program)

None of the ingredients is listed.

· OSHA-Ca (Occupational Safety & Health Administration)

None of the ingredients is listed.

12 Ecological information

- · Toxicity
- · Aquatic toxicity: No further relevant information available.
- Persistence and degradability No further relevant information available.
- Behavior in environmental systems:
- · Bioaccumulative potential No further relevant information available.
- Mobility in soil No further relevant information available.
- · Additional ecological information:
- · General notes: Not hazardous for water.
- Results of PBT and vPvB assessment
- **PBT:** Not applicable.
- · vPvB: Not applicable.

(Contd. on page 6)

US

Printing date 11/14/2022

Revision date 11/14/2022

(Contd. from page 5)

Trade name: CD4 Chimeric Monoclonal Antibody (Clone YNB46.1.8)

· Other adverse effects No further relevant information available.

13 Disposal considerations

· Waste treatment methods

• **Recommendation:** Smaller quantities can be disposed of with household waste.

· Uncleaned packagings:

• Recommendation: Disposal must be made according to official regulations.

• Recommended cleansing agent: Water, if necessary with cleansing agents.

14 Trans	hort Int	ormano	۱n
14 mans		ormatic	

· UN-Number · DOT, IMDG, IATA	not regulated
 UN proper shipping name DOT, IMDG, IATA 	not regulated
· Transport hazard class(es)	
· DOT, ADN, IMDG, IATA · Class	not regulated
 Packing group DOT, IMDG, IATA 	not regulated
· Environmental hazards:	Not applicable.
· Special precautions for user	Not applicable.
 Transport in bulk according to Annex II MARPOL73/78 and the IBC Code 	of Not applicable.
· UN "Model Regulation":	not regulated

15 Regulatory information

• Safety, health and environmental regulations/legislation specific for the substance or mixture No further relevant information available.

· Sara

Section 355 (extremely hazardous substances):

None of the ingredients is listed.

· Section 313 (Specific toxic chemical listings):

None of the ingredients is listed.

• TSCA (Toxic Substances Control Act):

7732-18-5 Water

· Hazardous Air Pollutants

None of the ingredients is listed.

(Contd. on page 7)

ACTIVE

US -

Printing date 11/14/2022

· Proposition 65

Revision date 11/14/2022

Trade name: CD4 Chimeric Monoclonal Antibody (Clone YNB46.1.8)

(Contd. from page 6)

· Chemicals	known to	cause cancer:	

None of the ingredients is listed.

· Chemicals known to cause reproductive toxicity for females:

None of the ingredients is listed.

· Chemicals known to cause reproductive toxicity for males:

None of the ingredients is listed.

· Chemicals known to cause developmental toxicity:

None of the ingredients is listed.

· Carcinogenic categories

· EPA (Environmental Protection Agency)

None of the ingredients is listed.

TLV (Threshold Limit Value)

None of the ingredients is listed.

• NIOSH-Ca (National Institute for Occupational Safety and Health)

None of the ingredients is listed.

• Chemical safety assessment: A Chemical Safety Assessment has not been carried out.

16 Other information

All chemicals may pose unknown hazards and should be used with caution. This SDS applies only to the material as packaged. If this product is combined with other materials, deteriorates, or becomes contaminated, it may pose hazards not mentioned in this SDS. Cayman Chemical Company assumes no responsibility for incidental or consequential damages, including lost profits, arising from the use of these data. It shall be the user's responsibility to develop proper methods of handling and personal protection based on the actual conditions of use. While this SDS is based on technical data judged to be reliable, Cayman Chemical Company assumes no responsibility for the completeness or accuracy of the information contained herein.

· Department issuing SDS: Environment protection department.

· Contact: -

- · Date of preparation / last revision 11/14/2022
- Abbreviations and acronyms:

IMDG: International Maritime Code for Dangerous Goods DOT: US Department of Transportation IATA: International Air Transport Association EINECS: European Inventory of Existing Commercial Chemical Substances ELINCS: European List of Notified Chemical Substances CAS: Chemical Abstracts Service (division of the American Chemical Society) NFPA: National Fire Protection Association (USA) HMIS: Hazardous Materials Identification System (USA) VOC: Volatile Organic Compounds (USA, EU) PBT: Persistent, Bioaccumulative and Toxic vPvB: very Persistent and very Bioaccumulative NIOSH: National Institute for Occupational Safety **OSHA: Occupational Safety & Health** TLV: Threshold Limit Value PEL: Permissible Exposure Limit **REL: Recommended Exposure Limit** * * Data compared to the previous version altered.